Cti Biopharma Corp Stock Working Capital

CTi Biopharma Corp fundamentals help investors to digest information that contributes to CTi Biopharma's financial success or failures. It also enables traders to predict the movement of CTi Stock. The fundamental analysis module provides a way to measure CTi Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CTi Biopharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CTi Biopharma Corp Company Working Capital Analysis

CTi Biopharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current CTi Biopharma Working Capital

    
  18.26 M  
Most of CTi Biopharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTi Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

In accordance with the company's disclosures, CTi Biopharma Corp has a Working Capital of 18.26 M. This is 95.71% lower than that of the Biotechnology sector and 96.61% lower than that of the Health Care industry. The working capital for all United States stocks is 98.76% higher than that of the company.

CTi Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTi Biopharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics of similar companies.
CTi Biopharma is currently under evaluation in working capital category among its peers.

CTi Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA